GlaxoSmithKline PLC - Full Rating Report - 2009/06/02 - Fitch Research

Report title: GlaxoSmithKline PLC

from Fitch Research
11 page (6879 word) report published Jun 02, 2009

Price $425.00 available for immediate download

Report Overview

Search Inside

About Fitch Research

...GSK's ratings are supported by its position as the thirdlargest player in the global pharmaceutical industry; its strong product portfolio and pipeline; good diversification in terms of product and geography, with 44% of 2008 pharmaceutical sales generated in the US; and strong profitability (operating profit margin in FY08: 33.9%). The latter is expected to be supported by the group's restructuring programme which was initiated in October 2007 and expanded in February 2009, and which is planned to deliver GBP1.7bn of savings by 2011 -- with pretax charges of GBP3.6bn (75% cash charges), of which 40% have already been incurred by May 2009. + ...

Report Type:

Full Rating Report

Company(ies):

GlaxoSmithKline plc

Ticker(s):

GSK

Issuer:

GlaxoSmithKline PLC

Free Sample:

Click Here to Download

Format:

PDF

Enter the keyword(s) which you would like to search for within this document and click "Search"

Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.

Also from Fitch Research

GlaxoSmithKline PLC $165.00
Fitch: European Pharma Faces Declining Profitability on Diversification Pressures $85.00
Global Pharmaceutical R&D Pipeline (First-Quarter 2009) $275.00
Fitch Downgrades GlaxoSmithKline to 'A+' on Stiefel Acquisition; Outlook Stable $85.00
Global Pharmaceutical R&D Pipeline (Fourth-Quarter 2008) $275.00
Fitch Global Pharmaceutical R&D Quarterly: 4th Qtr Regulatory Approvals Add to '08 Increases $85.00
GlaxoSmithKline PLC $165.00
Global Pharmaceutical R&D Pipeline (Third-Quarter 2008) $275.00

Price: $425.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.